| Literature DB >> 30100084 |
Shereen G Ghosh1, Kerstin Becker2, He Huang3, Tracy Dixon-Salazar1, Guoliang Chai1, Vincenzo Salpietro4, Lihadh Al-Gazali5, Quinten Waisfisz6, Haicui Wang2, Keith K Vaux7, Valentina Stanley1, Andreea Manole4, Ugur Akpulat8, Marjan M Weiss6, Stephanie Efthymiou4, Michael G Hanna4, Carlo Minetti9, Pasquale Striano9, Livia Pisciotta10, Elisa De Grandis10, Janine Altmüller11, Peter Nürnberg11, Holger Thiele11, Uluc Yis12, Tuncay Derya Okur12, Ayse Ipek Polat12, Nafise Amiri13, Mohammad Doosti14, Ehsan Ghayoor Karimani15, Mehran B Toosi16, Gabriel Haddad3, Mert Karakaya17, Brunhilde Wirth18, Johanna M van Hagen6, Nicole I Wolf19, Reza Maroofian20, Henry Houlden4, Sebahattin Cirak21, Joseph G Gleeson22.
Abstract
ADP-ribosylation, the addition of poly-ADP ribose (PAR) onto proteins, is a response signal to cellular challenges, such as excitotoxicity or oxidative stress. This process is catalyzed by a group of enzymes referred to as poly(ADP-ribose) polymerases (PARPs). Because the accumulation of proteins with this modification results in cell death, its negative regulation restores cellular homeostasis: a process mediated by poly-ADP ribose glycohydrolases (PARGs) and ADP-ribosylhydrolase proteins (ARHs). Using linkage analysis and exome or genome sequencing, we identified recessive inactivating mutations in ADPRHL2 in six families. Affected individuals exhibited a pediatric-onset neurodegenerative disorder with progressive brain atrophy, developmental regression, and seizures in association with periods of stress, such as infections. Loss of the Drosophila paralog Parg showed lethality in response to oxidative challenge that was rescued by human ADPRHL2, suggesting functional conservation. Pharmacological inhibition of PARP also rescued the phenotype, suggesting the possibility of postnatal treatment for this genetic condition. Published by Elsevier Inc.Entities:
Keywords: ADP-ribosylation; ADPRHL2; ARH3; SUDEP; ataxia; epilepsy; neurodegeneration; neuropathy; oxidative stress; poly-ADP ribose
Year: 2018 PMID: 30100084 PMCID: PMC6128219 DOI: 10.1016/j.ajhg.2018.07.010
Source DB: PubMed Journal: Am J Hum Genet ISSN: 0002-9297 Impact factor: 11.025